Nuvation Bio Inc
NUVB2.275USD
+0.045+2.02%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
773.14MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Nuvation Bio Inc Unternehmen
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Unternehmensinformationen
BörsenkürzelNUVB
Name des UnternehmensNuvation Bio Inc
IPO-datumJul 01, 2020
CEODr. David T. Hung, M.D.
Anzahl der mitarbeiter220
WertpapierartOrdinary Share
GeschäftsjahresendeJul 01
Addresse357 Tehama Street, Floor 3
StadtSAN FRANCISCO
BörseNYSE Consolidated
LandUnited States of America
Postleitzahl94103
Telefon14157543517
Websitehttps://www.nuvationbio.com/
BörsenkürzelNUVB
IPO-datumJul 01, 2020
CEODr. David T. Hung, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
60.28M
+0.84%
Mr. Kim D. Blickenstaff
Mr. Kim D. Blickenstaff
Independent Director
Independent Director
172.19K
--
Dr. Robert Mashal, M.D.
Dr. Robert Mashal, M.D.
Independent Director
Independent Director
100.00K
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
78.00K
+178.57%
Ms. Kerry A. Wentworth
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Chief Regulatory Officer
50.00K
--
Mr. Moses Makunje, CPA
Mr. Moses Makunje, CPA
Principal Accounting Officer, Vice President - Finance
Principal Accounting Officer, Vice President - Finance
10.61K
--
Ms. Stacy Markel
Ms. Stacy Markel
Chief People Officer
Chief People Officer
10.00K
--
Mr. Philippe Sauvage
Mr. Philippe Sauvage
Chief Financial Officer and Principal Financial Officer
Chief Financial Officer and Principal Financial Officer
7.30K
--
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Lead Independent Director
Lead Independent Director
5.00K
--
Mr. Joe Rayne
Mr. Joe Rayne
Investor Relations
Investor Relations
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
60.28M
+0.84%
Mr. Kim D. Blickenstaff
Mr. Kim D. Blickenstaff
Independent Director
Independent Director
172.19K
--
Dr. Robert Mashal, M.D.
Dr. Robert Mashal, M.D.
Independent Director
Independent Director
100.00K
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
78.00K
+178.57%
Ms. Kerry A. Wentworth
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Chief Regulatory Officer
50.00K
--
Mr. Moses Makunje, CPA
Mr. Moses Makunje, CPA
Principal Accounting Officer, Vice President - Finance
Principal Accounting Officer, Vice President - Finance
10.61K
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, May 16
Aktualisiert: Fri, May 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Hung (David T)
17.72%
Fidelity Management & Research Company LLC
14.70%
Decheng Capital LLC
7.63%
BlackRock Institutional Trust Company, N.A.
4.66%
The Vanguard Group, Inc.
4.51%
Other
50.78%
Aktionäre
Aktionäre
Anteil
Hung (David T)
17.72%
Fidelity Management & Research Company LLC
14.70%
Decheng Capital LLC
7.63%
BlackRock Institutional Trust Company, N.A.
4.66%
The Vanguard Group, Inc.
4.51%
Other
50.78%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
30.97%
Individual Investor
19.30%
Hedge Fund
12.40%
Investment Advisor/Hedge Fund
9.48%
Venture Capital
8.02%
Research Firm
1.03%
Bank and Trust
0.20%
Pension Fund
0.17%
Private Equity
0.01%
Other
18.42%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
340
277.65M
81.60%
-29.03M
2025Q1
346
276.31M
81.30%
-31.14M
2024Q4
336
290.52M
86.58%
+4.56M
2024Q3
324
278.55M
83.07%
+36.83M
2024Q2
323
221.78M
89.68%
-2.09M
2024Q1
305
194.38M
89.06%
-41.04M
2023Q4
290
194.02M
89.00%
-35.90M
2023Q3
285
196.95M
90.37%
-25.21M
2023Q2
286
199.03M
91.34%
-20.86M
2023Q1
290
197.27M
90.57%
-23.29M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Hung (David T)
60.28M
17.72%
+500.00K
+0.84%
Jun 16, 2025
Fidelity Management & Research Company LLC
50.03M
14.7%
+5.31M
+11.88%
Mar 31, 2025
Decheng Capital LLC
25.95M
7.63%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
15.87M
4.66%
-60.61K
-0.38%
Mar 31, 2025
The Vanguard Group, Inc.
15.34M
4.51%
-334.75K
-2.14%
Mar 31, 2025
Omega Fund Management, LLC
13.07M
3.84%
--
--
Mar 31, 2025
Laurion Capital Management LP
9.87M
2.9%
+3.38M
+52.06%
Mar 31, 2025
Octagon Capital Advisors LP
7.90M
2.32%
-1.30M
-14.16%
Mar 31, 2025
Geode Capital Management, L.L.C.
5.13M
1.51%
+179.41K
+3.62%
Mar 31, 2025
State Street Global Advisors (US)
4.86M
1.43%
+256.02K
+5.57%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Virtus LifeSci Biotech Clinical Trials ETF
0.97%
SPDR S&P Pharmaceuticals ETF
0.89%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.63%
ALPS Medical Breakthroughs ETF
0.45%
iShares U.S. Pharmaceuticals ETF
0.25%
iShares Micro-Cap ETF
0.11%
iShares Health Innovation Active ETF
0.08%
Avantis US Small Cap Equity ETF
0.06%
iShares Biotechnology ETF
0.05%
Fidelity Enhanced Small Cap ETF
0.04%
Mehr Anzeigen
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.97%
SPDR S&P Pharmaceuticals ETF
Anteil0.89%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Anteil0.63%
ALPS Medical Breakthroughs ETF
Anteil0.45%
iShares U.S. Pharmaceuticals ETF
Anteil0.25%
iShares Micro-Cap ETF
Anteil0.11%
iShares Health Innovation Active ETF
Anteil0.08%
Avantis US Small Cap Equity ETF
Anteil0.06%
iShares Biotechnology ETF
Anteil0.05%
Fidelity Enhanced Small Cap ETF
Anteil0.04%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
